Abstract：
BACKGROUND: Current guidelines for acute ischemic stroke recommend timely administration of intravascular thrombolytic therapy to promote functional and neurologic outcomes. Tenecteplase is an emerging off-label therapy for this indication and being utilized by various institutions due to its simpler administration strategy. In emergent situations in which intravenous access cannot be obtained, intraosseous access is a viable option for medication administration. However, there has been minimal published cases to support the efficacy and safety of intraosseous administration of tenecteplase for acute ischemic stroke.
METHODS: We describe the case of a 51-year-old woman who developed acute ischemic stroke within our institution. Due to difficulty achieving intravenous access and time-dependent efficacy of thrombolytic therapy, the decision was made to administer tenecteplase by the intraosseous route. Stroke symptoms improved within 48 hours following administration without complication.
CONCLUSIONS: Intraosseous administration of tenecteplase may be considered for treatment of acute ischemic stroke if intravenous access is unattainable.
METHODS: We describe the case of a 51-year-old woman who developed acute ischemic stroke within our institution. Due to difficulty achieving intravenous access and time-dependent efficacy of thrombolytic therapy, the decision was made to administer tenecteplase by the intraosseous route. Stroke symptoms improved within 48 hours following administration without complication.
CONCLUSIONS: Intraosseous administration of tenecteplase may be considered for treatment of acute ischemic stroke if intravenous access is unattainable.
摘要：
背景：目前的急性缺血性卒中指南建议及时给予血管内溶栓治疗以促进功能和神经系统预后。替奈普酶是针对该适应症的新兴标签外疗法，由于其更简单的给药策略而被各种机构使用。在无法获得静脉通路的紧急情况下，骨内通路是药物管理的可行选择。然而,目前已发表的病例很少支持替奈普酶骨内给药治疗急性缺血性卒中的有效性和安全性.
方法：我们描述了一个51岁女性在我们机构内发生急性缺血性卒中的案例。由于难以达到静脉通路和溶栓治疗的时间依赖性疗效，决定通过骨内途径给予替奈普酶.卒中症状在给药后48小时内改善，无并发症。
结论：如果无法通过静脉途径治疗急性缺血性卒中，可以考虑骨内给药替奈普酶。
方法：我们描述了一个51岁女性在我们机构内发生急性缺血性卒中的案例。由于难以达到静脉通路和溶栓治疗的时间依赖性疗效，决定通过骨内途径给予替奈普酶.卒中症状在给药后48小时内改善，无并发症。
结论：如果无法通过静脉途径治疗急性缺血性卒中，可以考虑骨内给药替奈普酶。
